



⁶ Applicant is to place a check mark here if English language Translation is attached.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/089,367		
		Filing Date	March 28, 2002		
		First Named Inventor	RAPPUOLI		
		Group Art Unit	Unassigned- 1645		
Examiner Name	Unassigned				
Sheet	2	of	4	Attorney Docket Number	2302-1651 (PP01651.102)


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SD	C1	ALMEIDA & ALPAR, "Nasal Delivery of Vaccines", <i>J. Drug Targeting</i> 3: 455-467.	
	C2	CAHILL et al., "Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles," <i>Vaccine</i> 13:455-462, 1995.	
	C3	CAHILL et al., "Mice are protected against Bordetella pertussis infection by intra-nasal immunization with filamentous haemagglutinin," <i>FEMS Microbiology Letters</i> 107: 211-216, 1993.	
	C4	Center for Disease Control and Prevention, "Pertussis Vaccination: Use of Acellular Pertussis Vaccines Among Infants AND young Children-recommendations of the Advisory Committee on Immunization Practices (ACIP)", <i>Morbid. Mortal. Weekly Rep.</i> 46 (RR-7): 1-25, 1997.	
	C5	DEL GIUDICE et al., "Molecular basis of vaccination," <i>Molecular Aspects of Medicine</i> 19: 1-70, 1998.	
	C7	DOUCE et al., "Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants," <i>PNAS USA</i> 92: 1644-1648, 1995.	
	C8	FONTANA et al., "Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit," <i>Infect. Immun.</i> 63: 2356-2360, 1995.	
	C9	GUSTAFSSON et al., "A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine," <i>N. Engl. J. Med.</i> 334: 349-355, 1996.	
	C10	GUZMAN et al., "Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid," <i>Infect. Immun.</i> 61: 573-579, 1993.	

Examiner Signature		Date Considered	April 06
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	10/089,367		
		Filing Date	March 28, 2002		
		First Named Inventor	RAPPUOLI		
		Group Art Unit	Unassigned 1645		
Examiner Name	Unassigned				
Sheet	3	of	4	Attorney Docket Number	2302-1651 (PP01651.102)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
S	C11	HAUSER et al., "Development and efficacy assessment of combination vaccines, with emphasis on acellular pertussis," <i>Dev. Biol. Stand.</i> 25: 251-255, 1998.	
	C12	JONES et al., "Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection," <i>Infect. Immun.</i> 64: 489-494, 1996.	
	C13	MILLS et al., "A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis," <i>Infect. Immun.</i> 66: 94-602, 1998.	
	C14	PARK et al., "The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes." <i>Exp. Mol. Med.</i> 32: 72-78, 2000.	
	C15	PODDA et al., "Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa," <i>Vaccine</i> 9: 741-745, 1991.	
	C16	RAPPUOLI et al., "Towards third-generation whooping cough vaccines," <i>Trends in biotechnology</i> 9: 232-238, 1991.	
	C17	RAPPUOLI, "Rational design of vaccines," <i>Nature Medicine</i> 3: 374-376, 1997.	
	C18	RYAN et al., "The adjuvant action of mutants of the heat labile toxin of E. coli for a nasally delivered acellular pertussis vaccine," <i>Immunology Letters</i> 69: 59, 1999.	
	C19	RYAN et al., "Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells," <i>Infection and Immunity</i> 67: 6270-6280, 1999.	
	C20	SHAHIN et al., "Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection," <i>Infect. Immun.</i> 60: 1482-1488, 1992.	
S	C21	SHAHIN et al., "Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres," <i>Infect. Immun.</i> 63: 1195-1200, 1995.	

Examiner Signature		Date Considered	April 06
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/089,367		
		Filing Date	March 28, 2002		
		First Named Inventor	RAPPUOLI		
		Group Art Unit	Unassigned 1665		
Examiner Name	Unassigned				
Sheet	4	of	4	Attorney Docket Number	2302-1651 (PP01651.102)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SD	C22	WALKER, "New strategies for using mucosal vaccination to achieve more effective immunization," <i>Vaccine</i> 12: 387-400, 1994.	
(Remaining rows are crossed out with a diagonal line)			

Examiner Signature	SD	Date Considered	Apr 7 06
-----------------------	----	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.